Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind vehicle-controlled study of 1% VVN461 ophthalmic solution with different dosing frequencies in Sjögren syndrome-associated dry eye
CTR20264020Phase 2Active
- Sponsor
- VivaVision Biotech
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VVN461 in dry eye syndrome (DED), sponsored by VivaVision Biotech. Started Oct 2026; status: active.
02
Drugs
VVN461
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20264020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264020.